文献类型： 外文期刊

作者： Zhan, Yixiang ¹ ; Ni, Kemin ¹ ; Liu, Zhaoce ¹ ; Xin, Ran ² ; Han, Qiurong ¹ ; Ping, Hangyu ² ; Liu, Yaohong ² ; Zhao, Xuanzhu ¹ ; Wang, Wanting ¹ ; Yan, Suying ¹ ; Sun, Jing ¹ ; Zhang, Qinghuai ¹ ; Wang, Guihua ⁶ ; Zhang, Zili ⁷ ; Zhang, Xipeng ¹ ; Hu, Xia ⁸ ; Li, Guoxun ¹ ; Zhang, Chunze ¹ ;

作者机构： 1.Tianjin Union Med Ctr, Dept Colorectal Surg, Tianjin 300121, Peoples R China

2.Nankai Univ, Sch Med, Tianjin, Peoples R China

3.Tianjin Inst Coloproctol, Tianjin, Peoples R China

4.Tianjin Univ Tradit Chinese Med, Sch Integrat Med, Tianjin, Peoples R China

5.Nankai Univ, Inst Translat Med, Tianjin Union Med Ctr, Tianjin, Peoples R China

6.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China

7.Tianjin Med Univ, Cent 3, Clin Coll, Tianjin, Peoples R China

8.Tianjin Acad Agr Sci, Inst Plant Protect, Dept Agr Insect, Tianjin, Peoples R China

期刊名称：SCIENTIFIC REPORTS （ 影响因子：4.6； 五年影响因子：4.9 ）

ISSN： 2045-2322

年卷期： 2023 年 13 卷 1 期

页码：

收录情况： SCI

摘要： We evaluate the prognostic value of chemotherapy and other prognostic factors on overall survival among colon patients with deficient mismatch repair (dMMR), and determine the optimum time to start chemotherapy after surgery. Data of 306 colon cancer patients with dMMR who received radical surgery were collected from three Chinese centers between August 2012 and January 2018. Overall survival (OS) was assessed with the Kaplan-Meier method and log-rank. Cox regression analysis were used to assess influencing prognosis factors. The median follow-up time for all patients was 45.0 months (range, 1.0-100). There was a nonsignificant OS benefit from chemotherapy for patients with stage I and stage II disease, including high-risk stage II disease (log-rank p: 0.386, 0.779, 0.921), and a significant OS benefit for patients with stage III and stage IV disease for receiving post-operation chemotherapy (log-rank p = 0.002, 0.019). Stage III patients benefitted from chemotherapy regimens that contained oxaliplatin (log-rank p = 0.004), and Starting chemotherapy with oxaliplatin treatment earlier resulted in better outcomes (95% CI 0.013-0.857; p = 0.035). Chemotherapy regimens containing oxaliplatin can prolong the survival time of stage III and IV dMMR colon cancer patients. This beneficial manifestation was more pronounced after starting chemotherapy treatment early post operation. High risk stage II dMMR colon patients including T4N0M0 cannot benefit from chemotherapy.